Sun offers $24.50 for Taro shares it doesn't own; Express-Medco deal faces another hearing;

@FiercePharma: Abbott plans to hive off its branded-biopharma business--$18B of its $40B sales--with EVP Richard Gonzalez as CEO News | Follow @FiercePharma

> Sun Pharmaceutical offered $24.50 per share for the remaining stock in Taro Pharmaceutical that it doesn't already own, valuing the company at about $1 billion. Article

> Express Scripts faces another congressional committee hearing on its proposed acquisition of fellow pharmacy benefits manager Medco Health Solutions. Item

> Merck's ($MRK) Irish unit is seeking volunteers to leave its County Wicklow facility, aiming to cut 40 jobs from the payroll. Report

> Perrigo asked FDA to approve its version of the Alcon Labs nasal spray patanase, while Alcon sued the company for patent infringement. Story

> Gilead Sciences ($GILD) breaks ground today on a $140 million R&D facility on its Foster City, CA campus. News

> PPD, the contract research organization that Carlyle Group and Hellman & Friedman want to buy for $3.9 billion, has another interested buyer who's signed a confidentiality agreement in return for more information on the company. Story

Biotech News

@FierceBiotech: Out of the gate yesterday, Sage Tx announces license deal with Ligand for Captisol tech for CNS drugs Item | Follow @FierceBiotech

@JohnCFierce: Thanks to Peter Mueller, Doug Williams, Omid Farokhzad, Tom Hughes and Stephen Knight for an interesting conversation on early stage R&D. | Follow @JohnCFierce

@RyanMFierce: Vertex's Mueller on open R&D: sharing IP gives you an opportunity to solve problems faster. A plug for open R&D? | Follow @RyanMFierce

> Arteaus launches with $18M from Atlas, OrbiMed. Article

> NextBio sees demand for translational research service. Piece

> PwC: Life Science VC funding dips in Q3 2011. Report

Medical Devices News

> Abbott to split into two companies. News

> Gore acquires NMT assets. Item

> Foundation Medicine raises $33.5M in expanded Series A. More

Drug Delivery News

> Santaris wins as delivery partner in Miragen's $352M deal. Article

> Halozyme gets boost from injectable Herceptin. Story

> Topica Pharma grabs $27M B round for topical antifungal drug. Article

> SkyePharma hit with European delay on Flutiform app. Piece

> Scientists find new pulse on gene therapy delivery. More

> Drug-delivery devices could run on power from the body. Report

And Finally... The list of aging-associated proteins known to be involved in cancer is growing longer. Article

Suggested Articles

Look out, diabetes market: Novo Nordisk won its FDA nod for highly anticipated Rybelsus to control blood sugar in patients with Type 2 diabetes.

Insys is in fire sale mode as part of its bankruptcy plan, and now it’s been given the go-ahead to sell the opioid that helped get it there.

GSK CEO Emma Walmsley could soon have a new title: Microsoft board member. The software giant has nominated her to its board of directors.